Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
NCT ID: NCT00134810
Last Updated: 2019-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
381 participants
INTERVENTIONAL
2005-03-31
2006-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
NCT00149240
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
NCT00447876
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
NCT00246155
Dysport® Adult Upper Limb Spasticity
NCT01313299
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
NCT01261611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin type A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Myofascial pain syndrome for more than 6 months
* Active trigger points in upper back
Exclusion Criteria
* Duration of myofascial pain syndrome no longer than 24 months
* Steroid injections during previous 3 months
* Anaesthetic injection at trigger points during previous 1 month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pain Treatment Centre, Anesthesiology & Resuscitation, St Ann Teaching Hospital
Brno, , Czechia
Dept Neurology, Teaching Hospital Olomouc
Olomouc, , Czechia
Institute of Rheumatology
Prague, , Czechia
Neurology Clinic, Klinikum der Ruhr-Universitat Bochum
Bochum, , Germany
Schmerzzentrum Frankfurt
Frankfurt am Main, , Germany
Schmerzzentrum Goppingen
Göppingen, , Germany
Klinik fur Anaesthesiologie und Intensivtherapie
Jena, , Germany
Neurologisch-Verhaltensmedizinische Schmerzklinik Kiel
Kiel, , Germany
Clinic for Neurology, Westfalische Wilhelmsuniversitat
Münster, , Germany
Aukammallee 33
Wiesbaden, , Germany
Fondazione Salvatore Maugeri
Montescano, , Italy
Azienda Ospedaliera di Padova
Padua, , Italy
Centrum Kliniczno-Badawcze
Elblag, , Poland
Osrodek Badan Klinicznych
Lublin, , Poland
Nasz Lekarz NZOZ Praktyka Grupowa Lekarzy
Torun, , Poland
Centrum Medyczne OSTEOMED NZOZ
Warsaw, , Poland
Hospital de Santa Maria
Lisbon, , Portugal
Hospital Univ Germans Trias i Pujol
Badalona, , Spain
Hospital de Traumatologia de la Vall d'Hebrón
Barcelona, , Spain
Hospedale Clinic I Provincial de Barcelona
Barcelona, , Spain
Hospital Universitari de Bellvitge
Barcelona, , Spain
Hospital Morales Meseguer
Murcia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-001845-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
Y-47-52120-722
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.